Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo

Dasatinib is a targeted cancer therapy, while programmed death ligand 1 (PD-L1) inhibitors are a form of immune checkpoint therapy used to treat various types of cancers. Several studies showed the potential efficacy of these drugs in the management of triple-negative breast cancer- an aggressive su...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Maha, Al-Asmakh (author)
مؤلفون آخرون: Bawadi, Hiba (author), Hamdan, Munia (author), Gupta, Ishita (author), Kheraldine, Hadeel (author), Jabeen, Ayesha (author), Rizeq, Balsam (author), Al Moustafa, Ala-Eddin (author)
التنسيق: article
منشور في: 2020
الموضوعات:
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.biopha.2020.111134
https://www.sciencedirect.com/science/article/pii/S0753332220313275
http://hdl.handle.net/10576/17228
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1857415084518670336
author Maha, Al-Asmakh
author2 Bawadi, Hiba
Hamdan, Munia
Gupta, Ishita
Kheraldine, Hadeel
Jabeen, Ayesha
Rizeq, Balsam
Al Moustafa, Ala-Eddin
author2_role author
author
author
author
author
author
author
author_facet Maha, Al-Asmakh
Bawadi, Hiba
Hamdan, Munia
Gupta, Ishita
Kheraldine, Hadeel
Jabeen, Ayesha
Rizeq, Balsam
Al Moustafa, Ala-Eddin
author_role author
dc.creator.none.fl_str_mv Maha, Al-Asmakh
Bawadi, Hiba
Hamdan, Munia
Gupta, Ishita
Kheraldine, Hadeel
Jabeen, Ayesha
Rizeq, Balsam
Al Moustafa, Ala-Eddin
dc.date.none.fl_str_mv 2020-12-21T10:49:44Z
2021-02-28
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://dx.doi.org/10.1016/j.biopha.2020.111134
Maha Al-Asmakh, Hiba Bawadi, Munia Hamdan, Ishita Gupta, Hadeel Kheraldine, Ayesha Jabeen, Balsam Rizeq, Ala-Eddin Al Moustafa, Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo, Biomedicine & Pharmacotherapy, Volume 134, 2021, 111134, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2020.111134.
07533322
https://www.sciencedirect.com/science/article/pii/S0753332220313275
http://hdl.handle.net/10576/17228
134
dc.language.none.fl_str_mv en
dc.publisher.none.fl_str_mv Elsevier
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Dasatinib
PD-L/PD-L1
Embryo
Angiogenesis
Chorioallantoic membrane
Toxicity
dc.title.none.fl_str_mv Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Dasatinib is a targeted cancer therapy, while programmed death ligand 1 (PD-L1) inhibitors are a form of immune checkpoint therapy used to treat various types of cancers. Several studies showed the potential efficacy of these drugs in the management of triple-negative breast cancer- an aggressive subtype of breast cancer, which can develop during pregnancy. Nevertheless, side effects of Dasatinib (DA) and PD-L1 drugs during pregnancy, especially in the early stages of embryogenesis are not explored yet. The aim of this study is to assess the individual and combined toxicity of DA and PD-L1 inhibitors during the early stages of embryogenesis and to evaluate their effect(s) on angiogenesis using the chorioallantoic membrane (CAM) model of the embryo. Our results show that embryos die at greater rates after exposure to DA and PD-L1 inhibitors as compared to their matched controls. Moreover, treatment with these drugs significantly inhibits angiogenesis of the CAM. To further elucidate key regulator genes of embryotoxicity induced by the actions of PD-L1 and DA, an RT-PCR analysis was performed for seven target genes that regulate cell proliferation, angiogenesis, and survival (ATF3, FOXA2, MAPRE2, RIPK1, INHBA, SERPINA4, and VEGFC). Our data revealed that these genes are significantly deregulated in the brain, heart, and liver tissues of exposed embryos, compared to matched control tissues. Nevertheless, further studies are necessary to evaluate the effects of these anti breast cancer drugs and elucidate their role during pregnancy.
eu_rights_str_mv openAccess
format article
id qu_e63659041878fd7ca4f21b170eeaade8
identifier_str_mv Maha Al-Asmakh, Hiba Bawadi, Munia Hamdan, Ishita Gupta, Hadeel Kheraldine, Ayesha Jabeen, Balsam Rizeq, Ala-Eddin Al Moustafa, Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo, Biomedicine & Pharmacotherapy, Volume 134, 2021, 111134, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2020.111134.
07533322
134
language_invalid_str_mv en
network_acronym_str qu
network_name_str Qatar University repository
oai_identifier_str oai:qspace.qu.edu.qa:10576/17228
publishDate 2020
publisher.none.fl_str_mv Elsevier
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
spelling Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryoMaha, Al-AsmakhBawadi, HibaHamdan, MuniaGupta, IshitaKheraldine, HadeelJabeen, AyeshaRizeq, BalsamAl Moustafa, Ala-EddinDasatinibPD-L/PD-L1EmbryoAngiogenesisChorioallantoic membraneToxicityDasatinib is a targeted cancer therapy, while programmed death ligand 1 (PD-L1) inhibitors are a form of immune checkpoint therapy used to treat various types of cancers. Several studies showed the potential efficacy of these drugs in the management of triple-negative breast cancer- an aggressive subtype of breast cancer, which can develop during pregnancy. Nevertheless, side effects of Dasatinib (DA) and PD-L1 drugs during pregnancy, especially in the early stages of embryogenesis are not explored yet. The aim of this study is to assess the individual and combined toxicity of DA and PD-L1 inhibitors during the early stages of embryogenesis and to evaluate their effect(s) on angiogenesis using the chorioallantoic membrane (CAM) model of the embryo. Our results show that embryos die at greater rates after exposure to DA and PD-L1 inhibitors as compared to their matched controls. Moreover, treatment with these drugs significantly inhibits angiogenesis of the CAM. To further elucidate key regulator genes of embryotoxicity induced by the actions of PD-L1 and DA, an RT-PCR analysis was performed for seven target genes that regulate cell proliferation, angiogenesis, and survival (ATF3, FOXA2, MAPRE2, RIPK1, INHBA, SERPINA4, and VEGFC). Our data revealed that these genes are significantly deregulated in the brain, heart, and liver tissues of exposed embryos, compared to matched control tissues. Nevertheless, further studies are necessary to evaluate the effects of these anti breast cancer drugs and elucidate their role during pregnancy.Elsevier2020-12-21T10:49:44Z2021-02-28Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.biopha.2020.111134Maha Al-Asmakh, Hiba Bawadi, Munia Hamdan, Ishita Gupta, Hadeel Kheraldine, Ayesha Jabeen, Balsam Rizeq, Ala-Eddin Al Moustafa, Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo, Biomedicine & Pharmacotherapy, Volume 134, 2021, 111134, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2020.111134.07533322https://www.sciencedirect.com/science/article/pii/S0753332220313275http://hdl.handle.net/10576/17228134enhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:qspace.qu.edu.qa:10576/172282024-07-23T11:23:12Z
spellingShingle Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
Maha, Al-Asmakh
Dasatinib
PD-L/PD-L1
Embryo
Angiogenesis
Chorioallantoic membrane
Toxicity
status_str publishedVersion
title Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
title_full Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
title_fullStr Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
title_full_unstemmed Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
title_short Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
title_sort Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
topic Dasatinib
PD-L/PD-L1
Embryo
Angiogenesis
Chorioallantoic membrane
Toxicity
url http://dx.doi.org/10.1016/j.biopha.2020.111134
https://www.sciencedirect.com/science/article/pii/S0753332220313275
http://hdl.handle.net/10576/17228